Uric acid level and the presence of metabolic syndrome: experiences from Vojvodina Region in Serbia by Popovic, DS et al.
 
 
Corresponding Author, E-mail: pitstop021@gmail.com; Fax: +38 1215 25081. 1Clinic for Endocrinology, Diabetes and Metabolic Disorders, 
2Emergency Center; Clinical Center of Vojvodina, Medical Faculty, University of Novi Sad, Serbia. Copyright: © 2015 The Authors. This 
is an open-access article distributed under the terms of the Creative Commons Attribution License. 
DS Popovic1*, E Stokic1, D Tomic-Naglic1, M Mitrovic1, B Vukovic2, D Benc1, T Icin1, B Kovacev-Zavisic1 
Diabesity 2015; 1(3): 24-28 doi: 10.15562/diabesity.2015.16 
www.diabesity.ejournals.ca 
ORIGINAL RESEARCH 
 
 
 
  
 
 
ABSTRACT 
 
Introduction: Uric acid level (UAL) might represent an indirect marker of metabolic syndrome (MS). Study 
investigates differences in UAL in the overall study group and in separate groups of normal weight, overweight 
and obese subjects, regarding the presence of MS. Patients and Methods: Cross sectional study included 1333 
participants. Anthropometrical measurements and relevant blood analysis were performed. For diagnosis of MS 
we used NCEP ATP III criteria. Results: 50.64% of the participants have fulfilled criteria for MS diagnosis. In 
the overall study group, participants with MS were older (p<0.0001), more often male (p=0.0025), had higher 
BMI (p<0.0001) and UAL (p=0.0003). In the group of obese subjects, participants with MS were also older 
(p<0.0001), more often male (p<0.0001), had higher BMI (p=0.0084) and UAL (p=0.0014). In both cases, 
stepwise logistic regression showed independent association of all four parameters, which significantly differed in 
univariate analysis, with MS. In the group of normal weight subjects, participants with MS were more often 
male (p=0.0001), while in overweight subjects, participants with MS were older (p=0.0005). Conclusion: UAL is 
higher in subjects with MS in the overall study group and in the group of obese subjects, but not in groups 
of normal weight and overweight persons. 
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Introduction 
Uric acid (UA) is the end product of nucleic 
acid metabolism. High levels of blood UA are 
associated with gout.1 Recent cohort studies suggest a 
causal relationship between hyperuricemia and risk of 
adverse cardiovascular events.2, 3 However, some of 
the studies fail to demonstrate this association after 
controlling for various atherosclerotic risk factors.4 
Nevertheless, UA level (UAL) might represent an 
indirect marker of metabolic syndrome (MS)5 and an 
indicator of “metabolically unhealthy” obesity6, a term 
which usually refers to the obese persons with 
developed MS. Determination of UAL could be of 
great importance, especially in populations, such is 
population of Vojvodina, where 58.5 % of citizens are 
overweight and obese.7   
Possible explanation for the association 
between higher waist circumference and hyperuricemia 
is generated from the evidence of independent 
correlation between UA and leptin levels, which could 
be a pathogenic factor responsible for UAL increase in 
obese patients.8  
Association of triglycerides and UA lays in the 
fact that synthesis of fatty acids in the liver is 
associated with the de novo synthesis of purine and 
accelerated UA production.9    
On the other hand, HDL cholesterol is 
associated with UA through action of insulin 
resistance.10 Association of insulin resistance and 
impaired glucose metabolism with UAL rises from the 
insulin-induced urinary sodium retention and 
consequent decreased UA clearance.11 Increased UAL 
are also associated with increased blood pressure 
through effects on the renin-angiotensin system and 
increased insulin resistance.6   
UA contributes in development of MS also 
through inducing proinflammatory response.1 This 
response is produced by the action of monosodium 
urate crystals, which directly trigger neutrophil 
activation, and indirectly activate NALP 3 
inflammasome, throughout Toll-like receptor 
mediation.1 It also increases the synthesis of monocyte 
chemoattractant protein 1.12  UA acts proatherogenic 
via upregulation of expression of platelet-derived 
growth factor13 and increase in proliferation of 
vascular smooth muscle cells.14   
Study investigates the differences in UAL 
between persons without and with diagnosed MS in 
the overall study group and in separate groups of 
normal weight, overweight and obese subjects. We 
presumed that UAL is independently associated with 
the presence of MS in all study groups and thus can be 
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used as an indirect marker of MS in the general 
population. 
 
Patients and Methods  
Cross sectional study included 1333 randomly 
selected patients, who came on regular health check 
examination at our outpatient clinic. Participants in 
study did not have previous history of diabetes, 
dyslipidemia or hypertension treatment and they were 
not taking any drugs which could affect the values of 
the analyzed parameters. Also, according to their 
knowledge, they were not suffering from any other 
acute or chronic illness which could have an effect on 
the analyzed parameters. 
  Study has been approved by the local ethics 
committee and it is performed according to Helsinki 
Declaration. All participants gave their written consent 
for partaking in the study. Patient’s general 
information and medical history were noted and 
physical examination was conducted. After that, 
anthropometrical measurements were performed. 
Body height was measured with Martin anthropometer 
with accuracy of 0.1 cm, while body weight was 
measured with professional medical body weight scale. 
Body mass index (BMI) was calculated as a ratio of 
body weight and square value of body height 
expressed in meters. Waist circumference was 
measured at the middle of the line connecting the 
anterior superior iliac crest bone and arch ribs with a 
centimeter tape with a precision of 0.1 cm. Blood 
pressure was measured using sphygmomanometer 
according to Riva-Rocci. The measurement was 
performed in sitting position, after 10-15 minutes of 
the rest period. Blood was sampled for analysis of 
fasting glucose, lipid and lipoprotein parameters 
(triglycerides and high density lipoprotein (HDL) 
cholesterol) and UA. Fasting glucose was analyzed 
with Dialab glucosa GOD-PAP method. For the 
determination of triglycerides we used standard 
enzymatic method. HDL cholesterol was analyzed 
with method of precipitation with sodium-phospho-
tungstate. UAL was determined with modified PAP 
method. 
For diagnosis of MS we used NCEP ATP III 
criteria (National Cholesterol Education Program, 
Adult Treatment Panel III, 2001).15 According to these 
guidelines, MS is defined with presence of three or 
more of the following risk determinants: increased 
waist circumference (>102 cm for men and >88 cm 
for women), elevated triglycerides (≥1.70 mmol/l), 
low HDL cholesterol (<1.03 mmol/l for men and 
<1.30 mmol/l for women), impaired fasting glucose 
(≥6.1 mmol/l) and hypertension (≥130/≥85 mmHg).  
In statistical processing of the data we used 
mean values, proportions, Student`s t-test, test of 
proportions, Pearson’s and Spearman’s correlation 
coefficients and stepwise logistic regression. 
 
Table 1. Characteristics of study group 
 
Parameter 
Mean value/proportion 
(n=1333) 
Age (years) 43.50 ± 10.43 
Male gender (%) 52.59 
Body mass index (kg/m2) 30.68 ± 7.55 
Waist circumference (cm) 98.11 ± 15.80 
Triglycerides (mmol/l) 2.08 ± 1.70 
HDL (mmol/l) 1.13 ± 0.26 
Fasting glucose (mmol/l) 5.18 ± 1.31 
Systolic blood pressure (mmHg) 134.08 ± 17.93 
Diastolic blood pressure (mmHg) 86.49 ± 12.25 
Uric acid (µmol/l) 310.15 ± 90.96 
 
 
Results 
Seven hundred and one participants were men (Table 
1). More than half of the examined participants have 
fulfilled criteria for MS diagnosis (50.64%). 
Hypertension had highest incidence of all MS risk 
determinants in the group with diagnosed MS and in 
the group without MS, as well (Figure 1). 
 
Figure 1. Incidence of detected risk determinants of MS in groups without 
and with diagnosed MS 
  
 
WC-waist circumference; TG-triglycerides; HDL-HDL cholesterol; FBG-
fasting blood glucose; BP-blood pressure 
 
As it was expected, incidence of obesity (BMI ≥ 30 
kg/m2) was pronouncedly higher in the group of 
participants with MS with regard to the group without 
MS (Figure 2). Understandably, participants with MS 
had higher BMI. They were older and more often 
male. Also, they had higher UAL (Table 2).  
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Table 2. Age, gender, BMI and UAL differences between groups without 
and with diagnosed MS in the overall study group 
 
Parameter 
No MS 
(n=658) 
MS 
(n=675) 
p value 
Age (years) 41.97 ± 10.41 45.00 ± 10.24 <0.0001* 
Male gender (%) 48.33 56.74 0.0025* 
BMI (kg/m2) 28.15 ± 6.27 33.15 ± 7.86 <0.0001* 
Uric acid (µmol/L) 300.99 ± 94.68 319.08 ± 86.32 0.0003* 
 
UAL did not show significant correlation with any of 
other analyzed parameters which significantly differed 
between two groups (age: r=0.02832, P=0.3016; male 
gender: rho=0.00630, P=0.8182; BMI: r=0.03479, 
P=0.2043). Stepwise logistic regression showed 
independent association of all included parameters 
(age, male gender, BMI and UAL) with MS (Table 3). 
 
Table 3. Stepwise logistic regression with MS as dependent variable and 
age, male gender, BMI and UAL as independent variables in the overall 
study group 
 
Parameter p value Odds ratio 
95% confidence 
interval 
Age <0.0001* 1.0316 1.0192-1.0441 
Male gender <0.0001* 2.4926 1.9029-3.2650 
BMI <0.0001* 1.1477 1.1240-1.1718 
Uric acid 0.0007* 1.0023 1.0010-1.0036 
 
Based on the BMI calculation, participants were 
classified into: normal weight (24.68%), overweight 
(30.38%) and obese (44.94%) groups. In the separate 
group of normal weight subjects, participants with MS 
were more often male, while other parameters did not 
show significant difference between two groups (Table 
4).  
 
Table 4. Age, gender, BMI and UAL differences between groups of 
normal weight subjects without and with diagnosed MS 
 
Parameter No MS (n=225) MS (n=74) p value 
Age (years) 39.83 ± 10.31 41.15 ± 12.54 0.3574 
Male gender (%)  52.55 78.38 0.0001* 
BMI (kg/m2) 22.72 ± 1.37 22.97 ± 1.34 0.1659 
Uric acid (µmol/l) 295.60 ± 85.63 313.38 ± 91.40 0.1224 
 
As far as for the separate group of overweight 
persons, subjects with MS were older, while other 
parameters also did not show significant difference 
between two groups (Table 5). 
 
Table 5. Age, gender, BMI and UAL differences between groups of 
overweight subjects without and with diagnosed MS 
 
Parameter 
No MS 
(n=210) MS (n=195) p value 
Age (years) 46.85 ± 8.17 49.49 ± 6.94 0.0005* 
Male gender (%)  68.57 73.33 0.3452 
BMI (kg/m2) 27.33 ± 1.40 27.58 ± 1.38 0.0714 
Uric acid (µmol/L) 312.79 ± 94.89 317.02 ± 87.30 0.6416 
 
With regard to the separate group of obese subjects, 
participants with diagnosed MS had higher BMI. They 
were older and more often male. Also, they had higher 
UAL (Table 6). 
  
Table 6. Age, gender, BMI and UAL differences between groups of 
obese subjects without and with diagnosed MS 
 
Parameter 
No MS 
(n=193) 
MS (n=406) p value 
Age (years) 39.47 ± 10.92 43.55 ± 10.41 <0.0001* 
Male gender (%)  20.73 44.83 <0.0001* 
BMI (kg/m2) 36.23 ± 4.96 37.69 ± 6.86 0.0084* 
Uric acid (µmol/L) 295.27 ± 104.65 321.11 ± 85.04 0.0014* 
 
UAL did not show significant correlation with any of 
other analyzed parameters which significantly differed 
between groups of obese subjects without and with 
diagnosed MS (age: r=-0.002491, P=0.9515; male 
gender: rho=0.0368, P=0.3681; BMI: r=0.004721, 
P=0.9082). Stepwise logistic regression showed 
independent association of all included parameters 
(age, male gender, BMI and UAL) with MS in obese 
subjects (Table 7) 
 
Table 7. Results of stepwise logistic regression with MS as dependent 
variable and age, male gender, BMI and UAL as independent variables 
in the group of obese subjects 
 
Parameter p value 
Odds 
ratio 
95% confidence 
interval 
Age 0.0078* 1.0251 1.0066-1.0440 
Male gender <0.0001* 4.4047 2.7452-7.0675 
BMI <0.0001* 1.1112 1.0695-1.1545 
Uric acid 0.0007* 1.0035 1.0014-1.0056 
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Figure 2. Incidence of normal weight (NW), overweight (OW) and 
obesity (OB) in groups without and with diagnosed MS 
 
 
NW-18.5 kg/m2 ≤ BMI < 25 kg/m2; OW-25 kg/m2 ≤ BMI < 30 kg/m2; 
OB-BMI ≥ 30 kg/m2 
Discussion and Conclusion  
It is widely known that obesity is associated 
with greater risk for developing MS. Association of 
hyperuricemia with obesity and MS was found by 
previous studies, as in adults16 and, also, in children.17 
One of the population based studies reported that an 
increment of one standard deviation of serum UAL is 
associated with a 35% higher MS likelihood in both 
sexes, independent of ten risk factors related to MS.18   
Similar to our results, previously conducted 
study showed that age and male gender are associated 
with greater risk for MS in adults.19   
As far as for separate MS components, earlier 
publications showed association of abdominal obesity 
and UAL in patients with high cardiovascular risk and 
normal UAL.20 Considering lipid and lipoprotein 
parameters, other investigators found association of 
triglycerides and HDL cholesterol with UAL in 
general population.21 Interestingly, association was also 
found between triglycerides to HDL cholesterol ratio 
and UAL, even independently of obesity and MS in 
the study which enrolled subjects without previous 
history of cardiovascular diseases.22 Follow-up study 
conducted by Finnish Diabetes Prevention Study 
Group showed that UAL and its changes during 
follow-up were related to corresponding changes in 
fasting and post load glucose and insulin levels in 
overweight and obese persons with impaired glucose 
tolerance.23. Cohort study which was performed in 
China reported that UAL is an independent predictor 
of blood pressure progression and incident 
hypertension in general population.24 
UAL is significantly higher in subjects with 
diagnosed MS in both overall study group and in the 
group of obese subjects, but not in normal weight and 
overweight groups. Multivariate analysis showed 
independent association of UAL and the presence of 
MS in both overall study group and in the group of 
obese subjects. This leads to the conclusion that UAL 
could be used as a marker of “metabolically 
unhealthy” phenotype, mainly in obese person. 
Considering the present knowledge of 
pathophysiological mechanisms of association 
between the UAL and the components of MS, analysis 
of serum UAL could detect obese persons who are at 
greater risk for developing metabolic complications 
and MS. Meta-analysis which will include a great 
number of studies dealing with role of UA in MS 
development could define what exact values of UA are 
associated with greater risk of MS development.       
The value of this study lays in the fact that it 
is conducted among subjects with different nutritional 
status, so it tested UAL in separate groups of normal 
weight, overweight and obese persons. The major 
limitation of this study is modest set of analyzed 
parameters and consequential lack of the data on other 
factors which are relevant for MS research. 
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